In January 2025, KDIGO - a global organization that is developing and implementing evidence-based clinical practice guidelines for kidney disease - released the first-ever guideline for the diagnosis and treatment of ADPKD.
Join Canadian nephrologist Dr. Matthew Lanktree and PKD patient partner Henry Osei-Agyekum as they discuss what the ADPKD Guideline means for healthcare providers and ADPKD patients, and answer common questions about the management and treatment of ADPKD.
This webinar will give patients better insight into the best, evidence-based ways to manage and treat ADPKD, and will include a live Q&A session.
Wednesday, March 26, 2025 at 7pm Eastern Time
The ADPKD Guideline provides healthcare providers, people living with ADPKD, and stakeholders with practical tools to improve diagnosis, care, and treatment, and address the complex challenges of managing this widespread inherited kidney disorder. The guideline spans topics such as disease nomenclature, diagnosis, prognosis, kidney and extrarenal manifestations, treatment strategies, and pregnancy and reproductive issues. The guideline also includes a dedicated chapter for issues related to children.
"This comprehensive guideline reflects the significant progress in ADPKD research over the last decade, from genetic insights to advanced therapies," said Guideline Co-Chair Vicente E. Torres, MD (United States). "By addressing the complexities of diagnosis, treatment, and management, we hope this guideline will standardize care, enhance clinical practices, and help reduce the global burden of ADPKD. Our goal is that this resource will not only empower clinical decision-making but also inspire hope for patients and their families, demonstrating that meaningful progress is achievable for this challenging disease."
About the Speakers
Dr. Matthew Lanktree is a clinician-scientist, assistant professor, and medical director of the McMaster Kidney Genetics Clinic, caring for patients with chronic and end-stage kidney disease at St. Joseph's Healthcare Hamilton and McMaster University. Dr. Lanktree has published extensively on genetics and kidney disease, including polycystic kidney disease, and has received peer review funding from the Canadian Institutes of Health Research, the Canadian and American Societies of Nephrology, and was recently awarded the Canadian Society of Nephrology New Investigator Award. Matt has set his goal to use genetics to improve the care of patients with kidney disease.
Henry Osei-Agyekum has experienced the impact of the disease firsthand, Having lost his mother to complications from PKD. With a deep personal connection to the cause, he is passionate about raising awareness, advocating for research, and supporting efforts to improve treatment options for those affected by PKD. Henry is dedicated to making a meaningful difference in the fight to end PKD.